FDA Holds Off On Biogenerics Decision
Sandoz, Novartis’ generics unit, said last week it received a letter from the FDA saying the agency found no deficiencies in its application. However, the agency added "uncertainty regarding scientific and legal issues" prompted it to delay action.
“We appreciate the constructive consultations held with the agency, and...
To view the full article, register now.